Doyle Mittie bought AVTX
May 5, 2026 · Form 4 insider transaction
Doyle Mittie bought 1,000 shares of Avalo Therapeutics, Inc. at $12.65 per share, a transaction worth $12.7K. The trade was recorded as option exercise under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 2 days after the transaction.
Direction
Acquired (buy-side)
Shares
1,000
Price
$12.65
Total value
$12.7K
InsiderDoyle Mittie
RoleOfficer, Director
SecurityCommon Stock
Transaction codeM: Option exercise
Transaction dateMay 5, 2026
Filing dateMay 7, 2026
Shares owned after4,622
OwnershipDirect
10b5-1 planYes
AmendedNo
Footnotes
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.